Welcome to our dedicated page for BiomX news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX stock.
BiomX Inc. (NYSE American: PHGE) is a pioneering clinical-stage microbiome and drug discovery company based in Israel. The company specializes in the development of natural and engineered phage therapies designed to target and destroy harmful bacteria associated with chronic diseases such as inflammatory bowel disease (IBD), colorectal cancer, primary sclerosing cholangitis, and chronic pulmonary infections in cystic fibrosis (CF) patients.
Utilizing advanced computational and synthetic biology research from globally renowned institutions, including the Weizmann Institute of Science and the Massachusetts Institute of Technology (MIT), BiomX's platforms discover and validate proprietary bacterial targets. Their flagship product candidate, BX004, aims to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients. This program has shown promising clinical results, achieving positive outcomes in both safety and efficacy in Part 2 of a Phase 1b/2a trial, with results expected to be published in November 2023. BX004 has been granted Fast Track designation by the FDA.
In addition to its CF program, BiomX has expanded its pipeline through a recent merger with Adaptive Phage Therapeutics (APT), adding BX211, a personalized phage treatment for diabetic foot osteomyelitis (DFO) caused by Staphylococcus aureus. This merger has bolstered BiomX's capabilities and financial resources, enabling the company to advance its clinical pipeline effectively.
BiomX enjoys strong backing from notable investors such as OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation, Takeda Ventures, Seventure Partners, Mirae Asset Global Investments, and SBI.
For more details on BiomX's ongoing projects and latest developments, visit www.biomx.com.
BiomX (NYSE American: PHGE) will host a conference call on
BiomX (NYSE: PHGE) reported its financial results for Q4 and the full year 2021, revealing a cash position of $63.1 million, up from $57.1 million in 2020. The company anticipates major clinical data readouts in 2022 for its cystic fibrosis (BX004) and atopic dermatitis (BX005) therapies. BiomX’s current cash runway supports operations through 2023, with potential for extension to mid-2024 via venture debt. The net loss for 2021 stood at $36.2 million, marking an increase from $30.1 million in 2020. A conference call is scheduled for today at 8:00 am ET.
BiomX Inc. (NYSE American: PHGE) has announced a conference call scheduled for March 30, 2022, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2021 financial results along with business updates. The company specializes in developing natural and engineered phage therapies targeting bacteria linked to chronic diseases like cystic fibrosis and colorectal cancer. Investors can access the live webcast via biomx.com.
BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.
BiomX (AMEX: PHGE) has announced a $5 million funding from the Cystic Fibrosis Foundation to support its Phase 1b/2a study of BX004, targeting chronic respiratory infections in cystic fibrosis patients. The funding will be provided in two tranches: an initial $3 million received in December 2021 and a potential additional $2 million upon completion of patient dosing. The study aims to assess the therapy's safety and efficacy, with results expected in 2022.
BiomX Inc. (PHGE), a clinical-stage microbiome company, announced its participation in two upcoming healthcare events: the Jefferies London Healthcare Conference from November 18-19, 2021 and the 2021 Phage Futures Congress Europe on November 23-24, 2021. At the Jefferies conference, an on-demand session will be presented by Jonathan Solomon, available from November 18. The Phage Futures Congress will feature a presentation titled “Nebulized Bacteriophage Therapy” by Myriam Golembo, Ph.D. on November 23. Webcasts will be accessible via the company's website.
BiomX (PHGE) announced a strategic shift to focus on its cystic fibrosis and atopic dermatitis programs, aiming for proof-of-concept data in 2022. The company has extended its cash runway to the end of 2023, supported by FDA clearance for its Phase 1b/2a trial in cystic fibrosis. BiomX will discontinue its acne program and postpone developments in inflammatory bowel disease and colorectal cancer.
As of September 30, 2021, BiomX reported a cash balance of $68.3 million and a net loss of $10 million for Q3 2021.
BiomX Inc. (NYSE American: PHGE) is set to hold a conference call on November 15, 2021, at 8:00 a.m. EDT to discuss third quarter 2021 financial results and provide business updates. The live audio webcast can be accessed through the company's website.
BiomX is a clinical-stage microbiome company focusing on novel phage therapies targeting pathogenic bacteria, impacting various chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX announced results from its Phase 2 clinical study of BX001, a topical treatment for acne. The study, involving 140 women with mild-to-moderate acne, met safety and tolerability endpoints with no adverse events reported. Statistically significant improvements were observed in skin appearance metrics, including inflammatory lesion counts (48.3% reduction, p<0.0001) and non-inflammatory lesions (36.3% reduction, p<0.0001). However, no meaningful efficacy difference was noted compared to the vehicle. Subject satisfaction indicated preference for BX001 in reducing redness and improving skin feel.
BiomX (NYSE: PHGE) has entered a licensing agreement with Maruho Co. Ltd., granting Maruho the right of first offer for BX005, a product targeting atopic dermatitis, set to begin after Phase 1/2 trial results in 2022. Additionally, Maruho will invest $3 million in BiomX, supporting the ongoing study. BX005 aims to combat Staphylococcus aureus to improve skin microbiome health. BiomX’s innovative phage-based approach highlights its potential in addressing dermatological issues. The announcement marks a significant collaboration in one of the largest dermatology markets.
FAQ
What is the current stock price of BiomX (PHGE)?
What is the market cap of BiomX (PHGE)?
What does BiomX Inc. specialize in?
What is BX004?
Who are BiomX's research partners?
What recent merger did BiomX complete?
Who are some of BiomX's investors?
What are some of BiomX's current projects?
Where is BiomX Inc. based?
What technological platforms does BiomX use?
When can we expect results for BX004 Phase 1b/2a trial?
How can I get more information about BiomX?
